| 28.06 | +0.22 / +0.79% |
Data as of 3:59pm ET | Day’s Change |
| 28.06 | |
Volume: -- |
The 5 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 28.00, with a high estimate of 36.00 and a low estimate of 27.50. The median estimate represents a -0.21% decrease from the last price of 28.06.

The current consensus among 9 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a rating.Move your mouse over past
months for detail

Move your mouse over a quarter or year to see how estimates have changed over time.




